TherOx is a part of ZOLL Medical Corporation. ZOLL TherOx is focused on improving treatment of acute myocardial infarction (AMI) with SuperSaturated Oxygen (SSO₂) Therapy. SSO₂ Therapy is a localized hyperoxemic oxygen infusion for the coronary arteries following AMI. SSO₂ Therapy is delivered via a catheter to the left main coronary artery in the cardiac catheterization laboratory following angioplasty and stenting. The superoxygenated infusion is delivered with an elevated pO2 content 7-10 times higher than normal arterial blood. The TherOx SSO₂ System includes three device components: a console, cartridge, and SSO₂ catheter. Together, these components create and deliver SSO₂ Therapy to the patient immediately following primary PCI for anterior STEMI. Multiple studies have shown that SSO₂ can reduce infarct size by 26% and improve left ventricular function. One year outcome data has demonstrated reductions in mortality and heart failure over PCI alone.